John Armitage’s Edwards Lifesciences EW Stock Holding History

John Armitage’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-4,019,847	Closed	-$146M	–	36
2017 Q3	$146M	Sell	4,019,847 -1,506,330	-27%	-$57.4M	1.31%	26
2017 Q2	$218M	Buy	+5,526,177	New	+$202M	2.18%	18

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

John Armitage's EW Position: Q4 2017 in Review

John Armitage sold out of Edwards Lifesciences (EW) in Q4 2017, closing a stake of 4,019,847 shares — an estimated $146M sold.

John Armitage first reported a position in EW in Q2 2017 and held it in 2 quarters. The position peaked at $218M in Q2 2017. 773 funds tracked by Wall St. Rank hold EW as of Q4 2017.

John Armitage reported no remaining Edwards Lifesciences position as of Q4 2017 after selling out during the quarter.
John Armitage sold 4,019,847 Edwards Lifesciences shares in Q4 2017, an estimated $146M.
John Armitage first reported a position in Edwards Lifesciences in Q2 2017 and held it in 2 quarters.
John Armitage's Edwards Lifesciences position peaked at $218M in Q2 2017.
773 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2017.

Based on Egerton Capital (UK)'s 13F filing for Q4 2017, filed 8 Feb 2018.